文献速递生殖医学

首次GnRH拮抗剂ICSI周期中α促卵泡素与β促卵泡素的累积活产率比较

Follitropin alpha versus beta in a first GnRH antagonist ICSI cycle: a retrospective cohort study.
PubMed 文献 · Reprod Biomed Online · 2021-07-24

回顾性单中心队列研究纳入832例首次ICSI周期不孕患者,分别使用Ovaleap(α促卵泡素,349例)或Puregon(β促卵泡素,483例)刺激,结果显示两组累积活产率无显著差异(57.0% vs 59.4%,P=0.49),多因素回归显示促性腺激素类型与累积活产率无关(P=0.28)。

要点

  • Ovaleap组刺激时间略长于Puregon组(10.6±1.7 vs 10.3±1.6天,P=0.012)。
  • 两组新鲜胚胎移植后生化妊娠率、临床妊娠率及活产率均无显著差异。
  • 多因素回归显示促性腺激素类型与累积活产率无显著关联(P=0.28)。

核心结论

  • 在首次GnRH拮抗剂ICSI周期中,Ovaleap与Puregon的累积活产率无显著差异。

研究设计与样本

  • 回顾性单中心队列研究,纳入2016年7月至2019年7月间832例首次ICSI周期不孕患者,每日FSH剂量150-225 IU。
  • Ovaleap组349例,Puregon组483例。

主要发现

  • 两组基线特征无统计学差异。
  • Ovaleap组刺激时间略长(10.6±1.7 vs 10.3±1.6天,P=0.012)。
  • 成熟卵母细胞数、受精率及胚胎利用率组间无显著差异。
  • 新鲜胚胎移植后生化妊娠率(39.3% vs 38.5%,P=0.83)、临床妊娠率(30.1% vs 31.5%,P=0.67)、活产率(26.9% vs 29.2%,P=0.48)及累积活产率(57.0% vs 59.4%,P=0.49)均无显著差异。
  • 多因素回归显示促性腺激素类型与累积活产率无关(P=0.28)。

临床怎么用

  • 在首次GnRH拮抗剂ICSI周期中,Ovaleap与Puregon可获得相似的累积活产率,选择时可综合考虑其他因素。

局限性

  • 回顾性单中心设计可能存在选择偏倚,结论需前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RESEARCH QUESTION: Are cumulative live birth rates (CLBR) after follitropin alpha (Ovaleap®) and follitropin beta (Puregon®) similar when used for ovarian stimulation with ICSI (intracytoplasmic sperm injection) in a first-rank gonadotrophin-releasing hormone (GnRH) antagonist protocol? DESIGN: Retrospective single-centre cohort study including 832 infertile patients undergoing ovarian stimulation with a daily dose of 150-225 IU FSH in their first ICSI cycle at a tertiary referral centre between July 2016 and July 2019. Of those, 349 patients used Ovaleap and 483 patients received Puregon. RESULTS: Baseline characteristics were not statistically different between the groups. The duration of stimulation was slightly longer in the Ovaleap group (10.6 ± 1.7 versus 10.3 ± 1.6 days; P = 0.012). The number of mature oocytes was not statistically different and there was no significant difference in fertilization rate or embryo utilization rate between the two groups. After fresh embryo transfer, biochemical pregnancy rate (137/349 [39.3%] versus 186/483 [38.5%]) as well as clinical pregnancy rate (105/349 [30.1%] versus 152/483 [31.5%]) were comparable (P = 0.83 and 0.67, respectively). Live birth rate (LBR) after fresh embryo transfer (94/349 [26.9%] versus 141/483 [29.2%]; P = 0.48) and CLBR (199/349 [57.0%] versus 287/483 [59.4%]; P = 0.49) were not significantly different. Multivariable regression analysis revealed that the type of gonadotrophin was not associated with CLBR (P = 0.28). CONCLUSION: This retrospective study shows no significant difference in CLBR between Ovaleap and Puregon in patients undergoing their first GnRH antagonist ICSI cycle.

来源:Reprod Biomed Online,查看原文。版权归原作者所有。

引用

  1. Van den Haute L, Drakopoulos P, Verheyen G, et al. Follitropin alpha versus beta in a first GnRH antagonist ICSI cycle: a retrospective cohort study. Reprod Biomed Online. 2021. PMID: 34474975. doi:10.1016/j.rbmo.2021.06.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。